EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|September 1, 2003
Pediatric Pointers
Author(s)Alison Palkhivala
San Francisco - Several recent studies have demonstrated some interesting phenomena in the area of pediatric dermatology. Howard B. Pride, M.D., an associate in the department of dermatology at Geisinger Health System in Danville, Pa., presented some highlights.
Advertisement
Advertisement
Related to this article
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5